<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02844842</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-ALE-2016-01</org_study_id>
    <nct_id>NCT02844842</nct_id>
  </id_info>
  <brief_title>Evaluation of Tolerability and Safety of &quot;Allergovac Poliplus&quot; in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice</brief_title>
  <acronym>APOLO</acronym>
  <official_title>Evaluation of Tolerability and Safety of &quot;Allergovac Poliplus&quot; in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roxall Medicina España S.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roxall Medicina España S.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational prospective study to assess the tolerability and safety of treatment
      of SCIT Allergovac Poliplus polymerized in depot presentation. The study drug will be
      administered either by a 1 day Schedule or by a rapid Schedule (3 increasing weekly doses at
      initiation period till maintenance dose is reached) The study population is both: adult and
      child, polysensitized to at least 2 allergen sources with rhinitis or allergic
      rhinoconjunctivitis. Patients may also present a concomitant mild or moderate asthma.

      The assignment of a patient to a particular therapeutic strategy will not be decided in
      advanced by a trial protocol but will be determined by routine clinical practice. The
      decision of the investigator to prescribe a particular treatment will be clearly dissociated
      from the decision to include the patient in the study. The patients will not suffer any
      intervention, whether diagnostic or monitoring, other than the usual in clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 23, 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity of adverse drug reactions</measure>
    <time_frame>From patient ICF signature till 1 week after last administered dose</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Rhinoconjunctivitis</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1 day initiation schedule</arm_group_label>
    <description>The initiation Schedule consists in administering 0.2 mL and 0.3 mL with 30 minutes of interval in the same day. Thus, the patient will reach the maintenance dose of 0.5 mL in one day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rapid initiation schedule</arm_group_label>
    <description>The patient will receive 3 increasing doses (0.1 mL + 0.3mL + 0.5 mL) weekly doses till the maintenance dose (0.5 mL) is reached.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allergovac Poliplus</intervention_name>
    <arm_group_label>1 day initiation schedule</arm_group_label>
    <arm_group_label>Rapid initiation schedule</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Polisensitized patients with allergic rinitis and rhinoconjunctivitis with or without
        associated mild or moderate asthma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged between 5 and 60 years who present rhinitis or allergic
             rhinoconjunctivitis caused by IgE-mediated sensitization to more than one allergen
             source with or without mild / moderate asthma.

          2. Patients eligible for immunotherapy treatment with Allergovac Poliplus according to
             investigator criteria.

          3. Patients must provide written informed consent. It is the case of children , the legal
             representative or tutor of the child must sign the inform consent form.

        Exclusion Criteria:

          1. Patients that according to the investigator criteria may present difficulties for
             understanding the patient information sheet, completing the questionnaires and
             self-administered scales.

          2. Patients that according to the investigator may present difficulties to complete the
             patient diary.

          3. Patients who are participating in another clinical trial or observational study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>C.H.U A Coruña</name>
      <address>
        <city>A Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopsital de Vinalopó</name>
      <address>
        <city>Elche</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Dr. Arias Irigoyen</name>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Dra. Victoria Moreno</name>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Lugo</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica de Asma y Alergia Dres. Ojeda</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Principe de Asturias</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Onteniente</name>
      <address>
        <city>Onteniente</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Tórax</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ntra. Sra de la Candelaria</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Manises</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Xátiva</name>
      <address>
        <city>Xátiva</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2016</study_first_submitted>
  <study_first_submitted_qc>July 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2016</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mild or moderate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

